Home/Pipeline/SimpleScreen CRC

SimpleScreen CRC

Colorectal Cancer Screening

Commercial (as LDT)Active

Key Facts

Indication

Colorectal Cancer Screening

Phase

Commercial (as LDT)

Status

Active

Company

Freenome

About Freenome

Freenome is a pioneering diagnostics company developing a multiomics and AI-powered platform for early cancer detection via blood tests. Founded in 2014 and headquartered in South San Francisco, the company's lead program is a blood-based screening test for colorectal cancer (CRC), which is undergoing validation in the large-scale PREEMPT CRC study. Freenome is also expanding its pipeline into lung cancer detection and aims to create a broad, accessible screening platform to improve cancer outcomes through earlier intervention.

View full company profile

Therapeutic Areas

Oncology

Other Colorectal Cancer Screening Drugs

Drug	Company	Phase	Status
Shield (ECLIPSE Study)	Guardant Health	FDA Approved	Commercial
Urine cfDNA Test for Colon Cancer Screening	JBS Science	Development	Active
iFOB	Pangea Laboratory	Commercial	Active
ColoHealth	New Day Diagnostics	Approved	Active
CRC Screening Program	Polymedco	Commercial	Active
ColoScape™ / QuantiDNA™	DiaCarta	Commercial	Active
ColoSense	Geneoscopy	Approved	Active
At-Home Colorectal Cancer Screening	SNT Biotech	Commercial	Active
FIT System & Assay Development	Sentinel Diagnostics	Commercial	Active
Next-Generation Cologuard®	Exact Sciences	Development	Active
ColoAlert®	Mainz Biomed	Pivotal Trial	Active (ReconAAsense FDA trial)